Published in J Immunol on December 01, 1982
A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J (1989) 3.62
Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci U S A (1990) 3.25
Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med (1991) 2.88
HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci U S A (1991) 2.83
HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J Exp Med (1993) 2.49
Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest (1991) 2.08
Hepatitis B virus (HBV)-specific cytotoxic T-cell response in humans: production of target cells by stable expression of HBV-encoded proteins in immortalized human B-cell lines. J Virol (1992) 1.94
Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways. J Virol (1994) 1.94
Association between hepatitis B virus and pancreatic cancer. J Clin Oncol (2008) 1.93
Natural history and prognostic factors for chronic hepatitis type B. Gut (1991) 1.75
An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol (1994) 1.68
Chronic active hepatitis in transgenic mice expressing interferon-gamma in the liver. Proc Natl Acad Sci U S A (1994) 1.49
A model for the hepatitis B virus core protein: prediction of antigenic sites and relationship to RNA virus capsid proteins. EMBO J (1988) 1.42
Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitope. Proc Natl Acad Sci U S A (1988) 1.41
Mutations in core nucleotide sequence of hepatitis B virus correlate with fulminant and severe hepatitis. J Clin Invest (1993) 1.38
Activation of class I major histocompatibility complex gene expression by hepatitis B virus. J Virol (1990) 1.37
Kinetics of acute hepatitis B virus infection in humans. J Exp Med (2001) 1.26
Trans-activation of HLA-DR gene by hepatitis B virus X gene product. Proc Natl Acad Sci U S A (1990) 1.22
Detection of pre-C and core region mutants of hepatitis B virus in chronic hepatitis B virus carriers. J Clin Invest (1991) 1.21
Autoantibody production in hepatitis B e antigen transgenic mice elicited with a self T-cell peptide and inhibited with nonself peptides. Proc Natl Acad Sci U S A (1991) 1.20
Variations in codons 84-101 in the core nucleotide sequence correlate with hepatocellular injury in chronic hepatitis B virus infection. J Clin Invest (1992) 1.18
Definition of hepatitis B virus (HBV)-specific target antigens recognized by cytotoxic T cells in acute HBV infection. Clin Exp Immunol (1987) 1.16
Induction of cytotoxic T cells to a cross-reactive epitope in the hepatitis C virus nonstructural RNA polymerase-like protein. J Virol (1992) 1.14
Selective sensitization of peripheral blood T lymphocytes to hepatitis B core antigen in patients with chronic active hepatitis type B. Clin Exp Immunol (1986) 1.14
Cell-mediated immunity to hepatitis B surface antigen in man. Clin Exp Immunol (1984) 1.14
Functional characterization of naturally occurring variants of human hepatitis B virus containing the core internal deletion mutation. J Virol (1998) 1.10
Cellular immunity to the hepatitis B virion in acute hepatitis type B. Clin Exp Immunol (1983) 1.08
Hepatitis B virus p25 precore protein accumulates in Xenopus oocytes as an untranslocated phosphoprotein with an uncleaved signal peptide. J Virol (1992) 1.05
Different hepatitis B virus core gene mutations in children with chronic infection and hepatocellular carcinoma. Gut (2003) 0.99
Antibody-directed complement-mediated cytotoxicity to hepatocytes from patients with chronic hepatitis B. Clin Exp Immunol (1995) 0.99
Role of hepatitis B virus infection in pathogenesis of IgA nephropathy. World J Gastroenterol (2003) 0.98
The affinity of anti-HBc antibodies in acute and chronic hepatitis B infection. Clin Exp Immunol (1990) 0.98
Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region. J Virol (1996) 0.97
Distribution of HBcAg in hepatitis B detected by immunoperoxidase staining with three different preparations of anti-HBc antibodies. J Clin Pathol (1989) 0.95
Immunological aspects of chronic active hepatitis. Clin Exp Immunol (1987) 0.94
Humoral and cellular immunogenecity of DNA vaccine based on hepatitis B core gene in rhesus monkeys. World J Gastroenterol (2001) 0.90
Relationship of HLA protein display to activation of 2-5A synthetase in HBe antigen or anti-HBe positive chronic HBV infection. Gut (1986) 0.88
Mutations in a hydrophilic part of the core gene of hepatitis C virus in patients with hepatocellular carcinoma in China. J Gastroenterol (1997) 0.88
Acute hepatitis in rats expressing human hepatitis B virus transgenes. Proc Natl Acad Sci U S A (1995) 0.87
Association between frequency of amino acid changes in core region of hepatitis B virus (HBV) and the presence of precore mutation in Japanese HBV carriers. J Gastroenterol (1997) 0.87
Immunohistological study of intrahepatic expression of hepatitis B core and E antigens in chronic type B hepatitis. J Clin Pathol (1992) 0.87
Natural killer activity in patients with acute viral hepatitis. Clin Exp Immunol (1986) 0.86
Establishment of a human T-cell clone cytotoxic for both autologous and allogeneic hepatocytes from chronic hepatitis patients with type non-A, non-B virus. Proc Natl Acad Sci U S A (1989) 0.85
In vitro study of IgG production and concanavalin A induced suppressor cell function in acute and chronic hepatitis B virus infection. Clin Exp Immunol (1986) 0.84
Analysis of viral proteins in circulating immune complexes from chronic carriers of hepatitis B virus. Clin Exp Immunol (1991) 0.83
The dynamics of hepatitis B virus infection. Proc Natl Acad Sci U S A (1996) 0.81
Cellular immunity to nucleocapsid and pre-S determinants in asymptomatic carriers of hepatitis B virus. Immunology (1987) 0.81
Hepatic expression of tumour necrosis factor-alpha in chronic hepatitis B virus infection. J Clin Pathol (1994) 0.81
Interleukin-21 responses in patients with chronic hepatitis B. J Interferon Cytokine Res (2014) 0.79
Characterization of cell mediated immune responses to the hepatitis B core protein in man. Clin Exp Immunol (1987) 0.79
Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles. PLoS One (2014) 0.78
Failure of exogenous interleukin 1 and interleukin 2 to correct decreased lymphocyte transformation in chronic hepatitis B virus carriers. Clin Exp Immunol (1987) 0.78
Impaired interleukin-2 receptor expression on lymphocytes from patients with chronic active hepatitis type B. Korean J Intern Med (1989) 0.77
In-vitro cell-mediated cytotoxicity for autologous liver cells in chronic non-A, non-B hepatitis. Clin Exp Immunol (1986) 0.77
Relative immunogenicity of hepatitis B virus-encoded antigens as targets for cytotoxic T-cell response. Immunology (1993) 0.77
Lymphocyte cytotoxicity to autologous hepatocytes in alpha 1-antitrypsin deficiency. Gut (1984) 0.77
Lymphocyte cytotoxicity for autologous hepatocytes. Gut (1984) 0.77
Liver disease. Postgrad Med J (1994) 0.76
Biochemical Rather than Virologic Response to Interferon Therapy may be More Closely Associated with Decrease of Hepatocellular Carcinoma Incidence in Patients with Chronic Hepatitis B. Gut Liver (2007) 0.75
T lymphocyte activation is associated with viral replication in chronic hepatitis B virus infection of childhood. Clin Exp Immunol (1991) 0.75
Immunological aspects of liver disease. Gut (1991) 0.75
Viral hepatitis. Gut (1991) 0.75
Chronic active hepatitis. Gut (1991) 0.75
Relationship between T-lymphocyte subsets and suppressor cell activity in patients with chronic active hepatitis B. Korean J Intern Med (1989) 0.75
Host immune response and variations in the virus genome: pathogenesis of liver damage caused by hepatitis B virus. Gut (1994) 0.75
Hepatology. Postgrad Med J (1991) 0.75
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
Early indicators of prognosis in fulminant hepatic failure. Gastroenterology (1989) 7.43
Cost analysis of early discharge after hip fracture. BMJ (1993) 6.64
Deaths from low dose paracetamol poisoning. BMJ (1998) 6.63
Anti-tuberculous therapy and acute liver failure. Lancet (1995) 6.27
Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med (2000) 6.07
Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med (2001) 6.05
Acute liver failure: redefining the syndromes. Lancet (1993) 4.99
Vulnerability genes or plasticity genes? Mol Psychiatry (2009) 4.96
Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet (1990) 4.57
Urinary D-glucaric-acid excretion as a test for hepatic enzyme induction in man. Lancet (1971) 4.49
Liver transplantation in man. I. Observations on technique and organization in five cases. Br Med J (1968) 4.38
Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet (1990) 4.27
Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med (1996) 4.10
Daily variation of particulate air pollution and poor cardiac autonomic control in the elderly. Environ Health Perspect (1999) 4.07
A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology (1994) 4.01
Cell-mediated immunity to a human liver-specific antigen in patients with active chronic hepatitis and primary biliary cirrhosis. Lancet (1972) 3.90
The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med (2000) 3.78
Inadequate antibody response to hBAg or suppressor T-cell defect in development of active chronic hepatitis. Lancet (1974) 3.61
Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess (2007) 3.40
Structured patient education: the diabetes X-PERT Programme makes a difference. Diabet Med (2006) 3.36
Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. N Engl J Med (1978) 3.28
Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med (1992) 3.24
HCV-associated liver cancer without cirrhosis. Lancet (1995) 3.23
NHLBI Family Heart Study: objectives and design. Am J Epidemiol (1996) 3.21
Lymphocyte cytotoxicity to isolated hepatocytes in chronic active hepatitis. Nature (1974) 3.17
Antibody-dependent cell-mediated (K cell) cytotoxicity against isolated hepatocytes in chronic active hepatitis. Lancet (1976) 3.16
Purification and characterization of human liver-specific membrane lipoprotein (LSP). Clin Exp Immunol (1977) 3.13
Improved survival after orthotopic liver grafting. Br Med J (Clin Res Ed) (1981) 3.09
Mutations that alter the ability of the Escherichia coli cyclic AMP receptor protein to activate transcription. Nucleic Acids Res (1990) 3.08
Presence of a newly described human DNA virus (TTV) in patients with liver disease. Lancet (1998) 3.06
Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg (1988) 3.04
Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet (1973) 2.98
Use of partial cardiopulmonary bypass during the anhepatic phase of orthotopic liver grafting. Lancet (1979) 2.98
Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ (1991) 2.94
More donor organs for transplantation. Elective ventilation proposals. J R Coll Physicians Lond (1993) 2.91
Multisystem involvement in chronic liver disease. Studies on the incidence and pathogenesis. Am J Med (1973) 2.88
Altered calcium metabolism in epileptic children on anticonvulsants. Br Med J (1971) 2.86
The arthropathy of idiopathic haemochromatosis. Q J Med (1968) 2.85
Hepatitis B virus infection in medical and health care personnel. Br Med J (Clin Res Ed) (1982) 2.85
Liver transplantation after paracetamol overdose. BMJ (1991) 2.81
New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol (1997) 2.78
Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet (1989) 2.76
Liver in Felty's syndrome. Br Med J (1970) 2.75
Hepatic damage and death from overdose of paracetamol. Lancet (1973) 2.70
Extrahepatic biliary atresia versus neonatal hepatitis. Review of 137 prospectively investigated infants. Arch Dis Child (1976) 2.67
Cyclosporin A in cadaveric organ transplantation. Br Med J (Clin Res Ed) (1981) 2.67
A test of the nature of cosmic acceleration using galaxy redshift distortions. Nature (2008) 2.65
Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med (1991) 2.65
Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology (1999) 2.62
Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology (1988) 2.60
Treatment of hepatic encephalopathy. N Engl J Med (1997) 2.60
Liver transplantation. Curr Probl Surg (1979) 2.57
Treatment of fulminant hepatic failure by polyacrylonitrile-membrane haemodialysis. Lancet (1977) 2.53
Acute liver failure secondary to hepatic infiltration: a single centre experience of 18 cases. Gut (1998) 2.51
Orthotopic liver transplantation: the first 60 patients. Br Med J (1977) 2.50
A habitable fluvio-lacustrine environment at Yellowknife Bay, Gale crater, Mars. Science (2013) 2.50
The systemic inflammatory response syndrome in acute liver failure. Hepatology (2000) 2.47
Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology (2000) 2.45
Attentional bias in anxiety and depression: the role of awareness. Br J Clin Psychol (1995) 2.43
Developing and deploying a patient safety program in a large health care delivery system: you can't fix what you don't know about. Jt Comm J Qual Improv (2001) 2.42
Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med (1995) 2.41
Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med (1980) 2.41
1 -Antitrypsin deficiency and neonatal hepatitis. Br Med J (1972) 2.40
General practice orthopaedic outpatient referrals in North Staffordshire. Br Med J (Clin Res Ed) (1983) 2.38
Relation of renal impairment and haemorrhagic diathesis to endotoxaemia in fulminant hepatic failure. Lancet (1974) 2.37
Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations. Adv Exp Med Biol (1997) 2.35
Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology (1993) 2.32
Niemann-Pick disease type C: diagnosis and outcome in children, with particular reference to liver disease. J Pediatr (1993) 2.32
Long-term anticonvulsant therapy worsens outcome in paracetamol-induced fulminant hepatic failure. Hum Exp Toxicol (1992) 2.31
Influence of delta infection on severity of hepatitis B. Lancet (1982) 2.31
Increased long-term survival in variceal haemorrhage using injection sclerotherapy. Results of a controlled trial. Lancet (1982) 2.30
Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology (1993) 2.29
Treatment of secondary hepatic tumours by ligation of hepatic artery and infusion of cytotoxic drugs. Lancet (1970) 2.25
Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut (2004) 2.22
Long term effect of alpha interferon in children with chronic hepatitis B. Gut (2000) 2.21
Cytomegalovirus hepatitis in the adult. Lancet (1967) 2.20
Serial prothrombin time as prognostic indicator in paracetamol induced fulminant hepatic failure. BMJ (1990) 2.18
Detection of hepatitis-B antigen by radioimmunoassay in chronic liver disease and hepatocellular carcinoma in Great Britain. Lancet (1973) 2.17
Assessment of non-mydriatic fundus photography in detection of diabetic retinopathy. Br Med J (Clin Res Ed) (1986) 2.16
Fasting proinsulin concentrations predict the development of type 2 diabetes. Diabetes Care (1999) 2.16
Portal hypertension in idiopathic tropical splenomegaly. Lancet (1966) 2.16
Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet (1968) 2.14